home / stock / alec / alec quote
Last: | $ |
---|---|
Change Percent: | 0.87% |
Open: | $30.00 |
Close: | $30.26 |
High: | $31.10 |
Low: | $29.47 |
Volume: | 421,893 |
Last Trade Date Time: | 02/12/2020 04:40:05 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $30.00 | $30.26 | $31.10 | $29.47 | 421,893 | 02-12-2020 |
$ | $28.91 | $30.00 | $32.4799 | $28.88 | 971,527 | 02-11-2020 |
$ | $35.49 | $29.26 | $35.675 | $28.05 | 1,811,252 | 02-10-2020 |
$ | $34.27 | $35.28 | $35.93 | $33.95 | 1,518,884 | 02-07-2020 |
$ | $34.19 | $34.47 | $35.00 | $33.47 | 732,350 | 02-06-2020 |
$ | $31.98 | $33.71 | $34.4299 | $30.97 | 1,133,504 | 02-05-2020 |
$ | $28.89 | $30.18 | $31.00 | $28.76 | 1,274,669 | 02-04-2020 |
$ | $27.81 | $28.19 | $28.51 | $27.59 | 611,476 | 02-03-2020 |
$ | $28.30 | $27.94 | $28.6283 | $26.67 | 639,205 | 01-31-2020 |
$ | $27.00 | $28.17 | $28.75 | $25.40 | 3,518,159 | 01-30-2020 |
$ | $25.11 | $25.94 | $26.98 | $25.08 | 696,949 | 01-29-2020 |
$ | $25.60 | $24.59 | $26.00 | $23.77 | 689,194 | 01-28-2020 |
$ | $24.77 | $25.73 | $26.07 | $24.40 | 910,505 | 01-27-2020 |
$ | $23.80 | $24.55 | $24.99 | $23.70 | 661,688 | 01-24-2020 |
$ | $25.21 | $23.275 | $25.45 | $23.24 | 988,009 | 01-23-2020 |
$ | $22.01 | $22.93 | $23.18 | $21.7122 | 409,839 | 01-22-2020 |
$ | $21.20 | $21.99 | $22.13 | $20.985 | 338,780 | 01-21-2020 |
$ | $20.06 | $21.38 | $21.84 | $19.86 | 568,371 | 01-20-2020 |
$ | $20.06 | $21.38 | $21.84 | $19.86 | 566,769 | 01-17-2020 |
$ | $19.19 | $19.89 | $20.04 | $19.0614 | 328,140 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
2024-03-18 01:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in...